Received Oct 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | — | — |
tested positive for COVID- 19 for the first time; tested positive for COVID- 19 for the first time; This is a literature report for the following literature source(s) A 15-year-old female patient received BNT162b2 (BNT162B2), in 2021 as dose 1, single (Batch/Lot number: unknown) and in Jun2021 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Sjogren's disease" (ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2021, outcome "unknown" and all described as "tested positive for COVID- 19 for the first time". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: positive. Clinical course: the patient had received mRNA coronavirus disease 2019 (COVID-19) vaccine (Pfizer/BioNTech) earlier that year (2021), with the second vaccination (June 2021) occurring approximately 7 weeks before the reported onset of symptoms. She had no known recent exposures to COVID-19 or mononucleosis. Two months after hospital discharge, she developed chest pain and cough with blood-tinged mucus and tested positive for COVID-19 for the first time.; Sender's Comments: Vaccine efficacy varies from person to person and is affected by many factors. The association between the event lack of effect/drug ineffective (COVID-19) with the suspect product BNT162B2 cannot be fully excluded.,Linked Report(s) : US-PFIZER INC-PV202500125702 Same article/drug/patient and different event;
Sjogren's disease
Test Name: COVID- 19; Test Result: Positive